
Thomas Mikeska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7811882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	7.0	79
2	Assessing alternative base substitutions at primer CpG sites to optimise unbiased PCR amplification of methylated sequences. Clinical Epigenetics, 2017, 9, 31.	4.1	10
3	Epigenetic Basis of Human Cancer. , 2017, , 83-102.		1
4	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget, 2017, 8, 83626-83636.	1.8	13
5	Fc-Î ³ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 2435-2444.	7.0	33
6	MethPat: a tool for the analysis and visualisation of complex methylation patterns obtained by massively parallel sequencing. BMC Bioinformatics, 2016, 17, 98.	2.6	22
7	Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. BMC Cancer, 2015, 15, 669.	2.6	14
8	Exemplary multiplex bisulfite amplicon data used to demonstrate the utility of Methpat. GigaScience, 2015, 4, 55.	6.4	3
9	DNA Methylation Biomarkers: Cancer and Beyond. Genes, 2014, 5, 821-864.	2.4	236
10	No evidence for PALB2 methylation in high-grade serous ovarian cancer. Journal of Ovarian Research, 2013, 6, 26.	3.0	8
11	Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations. Clinical Cancer Research, 2013, 19, 3474-3484.	7.0	76
12	No evidence for DNA methylation of theATMpromoter CpG island in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1420-1422.	1.3	4
13	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 2012, 18, 1224-1231.	30.7	406
14	RANK (TNFRSF11A) Is Epigenetically Inactivated and Induces Apoptosis in Gliomas. Neoplasia, 2012, 14, 526-IN12.	5.3	25
15	DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Review of Molecular Diagnostics, 2012, 12, 473-487.	3.1	146
16	1.31 Investigating Methylation of the Pro-Apoptotic CLL Tumour Suppressor Gene, Death Associated Protein Kinase 1 (DAPK1). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S159.	0.4	0
17	Analysing DNA Methylation Using Bisulphite Pyrosequencing. Methods in Molecular Biology, 2011, 791, 33-53.	0.9	61
18	Closed-Tube PCR Methods for Locus-Specific DNA Methylation Analysis. Methods in Molecular Biology, 2011, 791, 55-71.	0.9	12

ΤΗΟΜΑS ΜΙΚΕSKA

#	Article	IF	CITATIONS
19	Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Research and Treatment, 2011, 130, 319-329.	2.5	16
20	p75 ^{NTR} induces apoptosis in medulloblastoma cells. International Journal of Cancer, 2011, 128, 1804-1812.	5.1	22
21	Assessing combined methylation–sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics, 2011, 6, 500-507.	2.7	61
22	A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues. BMC Biotechnology, 2010, 10, 89.	3.3	17
23	DNA methylation analysis of the HIFâ€1α prolyl hydroxylase domain genes <i>PHD1</i> , <i>PHD2</i> , <i>PHD3</i> and the factor inhibiting HIF gene <i>FIH</i> in invasive breast carcinomas. Histopathology, 2010, 57, 451-460.	2.9	15
24	The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics, 2010, 2, 561-573.	2.1	126
25	Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. Cancer Research, 2010, 70, 1689-1699.	0.9	66
26	A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. Human Molecular Genetics, 2009, 18, 1755-1768.	2.9	55
27	Validation of a primer optimisation matrix to improve the performance of reverse transcription – quantitative real-time PCR assays. BMC Research Notes, 2009, 2, 112.	1.4	31
28	Quality control of astrocyteâ€directed Cre transgenic mice: The benefits of a direct link between loss of gene expression and reporter activation. Glia, 2009, 57, 680-692.	4.9	22
29	Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated Bâ€Raf. International Journal of Cancer, 2009, 125, 297-307.	5.1	36
30	MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays. Genome Biology, 2009, 10, R105.	9.6	25
31	Aberrant Methylation and Reduced Expression of LHX9 in Malignant Gliomas of Childhood. Neoplasia, 2009, 11, 700-711.	5.3	36
32	Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics and Chromatin, 2008, 1, 7.	3.9	65
33	In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. British Journal of Cancer, 2008, 99, 294-304.	6.4	17
34	Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Research, 2008, 36, e42-e42.	14.5	159
35	Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. Journal of Molecular Diagnostics, 2007, 9, 368-381.	2.8	194
36	Mutations of the Wnt antagonistAXIN2(Conductin) result in TCF-dependent transcription in medulloblastomas. International Journal of Cancer, 2007, 121, 284-291.	5.1	60

ΤΗΟΜΑS ΜΙΚΕSKA

#	Article	IF	CITATIONS
37	Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. International Journal of Cancer, 2007, 121, 547-554.	5.1	65
38	SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas. Oncogene, 2007, 26, 5662-5668.	5.9	25
39	Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene, 2006, 25, 4890-4903.	5.9	61
40	CpG Island Methylation in Human Lymphocytes Is Highly Correlated with DNA Sequence, Repeats, and Predicted DNA Structure. PLoS Genetics, 2006, 2, e26.	3.5	183
41	BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics, 2005, 21, 4067-4068.	4.1	554
42	Crystal structures of O-acetylated 2-acylamino-2-deoxy-d-galactose derivatives. Carbohydrate Research, 2003, 338, 2119-2128.	2.3	2
43	(4S,5S)-4-[(1R)-1,2-Dihydroxyethyl]-5-tridecyl-1,3-oxazolidin-2-one. Acta Crystallographica Section C: Crystal Structure Communications, 2003, 59, o225-o227.	0.4	2
44	6(S)-Methyl-3(S)-(1-methylethyl)piperazin-2-one. Acta Crystallographica Section E: Structure Reports Online, 2003, 59, o171-o173.	0.2	0
45	1,1-DimethylethylN-propanoylcarbamate. Acta Crystallographica Section E: Structure Reports Online, 2003, 59, o1359-o1361.	0.2	2
46	tert-Butyl 4-acetyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2002, 58, o359-o361.	0.2	1
47	2(S)-N-tert-Butoxycarbonylamino-N-methoxy-N-methylbutanamide. Acta Crystallographica Section E:	0.2	1